Arcutis Biotherapeutics, Inc.
ZORYVE
atopic dermatitis
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews ZORYVE for atopic dermatitis around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Submitted an sNDA for ZORYVE cream 0.05% to the FDA to expand the indication for the treatment of mild to moderate atopic dermatitis in infants ages 3 to 24 months.”